Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30483102 | 0.97 | CA1 (0.46) | CA1CA2NAMPTCYP17A1HDAC3 | |
| SCHEMBL8693590 | 0.91 | CA1 (0.54) | CA1CA2NAMPTCYP17A1HDAC3 | |
| SCHEMBL15295619 | 0.89 | NAMPT (0.49) | CA1CA2NAMPTCYP17A1HDAC3 | |
| SCHEMBL17874907 | 0.86 | HPGD (0.50) | CA1CA2NAMPTCYP17A1HDAC3 | |
| SCHEMBL10850707 | 0.85 | CA1 (0.50) | CA1CA2NAMPTCYP17A1HDAC3 | |
| SCHEMBL14679376 | 0.85 | POLB (0.54) | CA1CA2HDAC3HDAC1HDAC10 | |
| SCHEMBL10845806 | 0.85 | POLB (0.53) | CA1CA2NAMPTHDAC3HDAC1 | |
| SCHEMBL7722182 | 0.85 | CYP17A1 (0.53) | CA1CA2NAMPTCYP17A1PTPN11 | |
| SCHEMBL245094 | 0.85 | CYP17A1 (0.61) | CA1NAMPTCYP17A1HDAC3PTPN11 | |
| SCHEMBL400342 | 0.84 | CA1 (0.49) | CA1CA2NAMPTCYP17A1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD THERAPEUTICS LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024020379-A2 | PRODRUGS, PRODRUG COMPOSITIONS AND RELATED METHODS | PRAESIDIA BIOTHERAPEUTICS INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-117355337-A | Protein-macromolecule conjugates and methods of use thereof | 奥迪曼药业科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4114417-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022212362-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| WO-2021178818-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-09-10 | — | — | WO | disclosed |
| WO-2018143145-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | 中外製薬株式会社 | 2018-08-09 | — | — | WO | disclosed |
| WO-2017147146-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS | Concentric Analgesics, Inc. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20130280204-A1 | Polymer-Attached Inhibitors of Influenza Virus | NATIONAL INSTITUTES OF HEALTH | 2013-10-24 | — | — | US | disclosed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-7371755-B1 | Antiviral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2008-05-13 | — | — | US | disclosed |
| EP-1214317-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019822-A1 | ANTIVIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2001-03-22 | — | — | WO | disclosed |
| US-5571836-A | NEURAMINIC ACID DERIVATIVES | BOVIN NICOLAI V (RU) | 1996-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | CA1 271/4885CA2 1240/4885NAMPT 2124/4885 |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, MACROD1, MSN | CA1 3853/4885CA2 4805/4885NAMPT 2205/4885 |
| US-20130280204-A1 | Polymer-Attached Inhibitors of Influenza Virus | PARG, PARN, SARS1 | CA1 967/4885CA2 3158/4885NAMPT 1110/4885 |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | TLR9, STING1, TLR3 | CA1 3710/4885CA2 2073/4885NAMPT 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.